A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee

July 4, 2014 updated by: Boehringer Ingelheim

Open Study to Access the Efficacy and Safety of Meloxicam 7.5mg in Patients With Osteoarthritis of the Knee

To Access the Efficacy and Safety of Meloxicam 7.5mg once daily over a treatment period of 56 days

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Phase 4

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

34 years to 74 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

- Osteoarthritis of the knee requiring the therapy with non-steroidal anti-inflammatory drugs (NSAIDs)

Exclusion Criteria:

none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Meloxicam
Drug: Meloxicam
Other Names:
  • Mobic

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change from baseline in pain on active movement assessed by a 100 mm visual analogue scale (100 mm, VAS)
Time Frame: Baseline, 8 weeks after first drug administration
Baseline, 8 weeks after first drug administration

Secondary Outcome Measures

Outcome Measure
Time Frame
Change from baseline in Lequesne index
Time Frame: Baseline, 8 weeks after first drug administration
Baseline, 8 weeks after first drug administration
Change from baseline in physical examination (tenderness)
Time Frame: Baseline, 8 weeks after first drug administration
Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in status according endoscopy
Time Frame: Baseline, 8 weeks after first drug administration
Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in gastrointestinal (GI) symptoms score
Time Frame: Baseline, 8 weeks after first drug administration
Baseline, 8 weeks after first drug administration
Assessment of significant change from baseline in laboratory values
Time Frame: Baseline, 8 weeks after first drug administration
Baseline, 8 weeks after first drug administration
Number of Patients with Adverse Events
Time Frame: Up to 8 weeks after first drug administration
Up to 8 weeks after first drug administration
Assessment of significant change from baseline in physical examination (swelling)
Time Frame: Baseline, 8 weeks after treatment
Baseline, 8 weeks after treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 1998

Primary Completion (Actual)

February 1, 1999

Study Registration Dates

First Submitted

July 4, 2014

First Submitted That Met QC Criteria

July 4, 2014

First Posted (Estimate)

July 8, 2014

Study Record Updates

Last Update Posted (Estimate)

July 8, 2014

Last Update Submitted That Met QC Criteria

July 4, 2014

Last Verified

July 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 107.228

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis

Clinical Trials on Meloxicam

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe